Advance the clinical development of TylAMac as a macrofilaricidal treatment that targets Wolbachia bacteria
current phase of drug development
updated 1 Jun 2021
The filarial worms that cause river blindness are dependent on the worm-symbiont Wolbachia bacteria for growth, development, reproduction, and survival. An antibiotic drug that targets the symbiont would cause the filarial worms to die, offering a new and practical treatment for this deadly disease.
TylAMac, or ABBV-4083, is a derivative of tylosin, a veterinary antibiotic that targets Wolbachia. The compound was identified through screening of anti-infective compounds led by AbbVie and the anti-Wolbachia consortium A-WOL at the Liverpool School of Tropical Medicine. TylAMac is currently in clinical development for the treatment of filarial diseases. TylAMac is orally available, induces a robust anti-Wolbachia effect in several in vivo models, demonstrates clear superiority over the current treatment doxycycline, and is effective after a shorter dosing regimen.
First-in-human Phase I studies for TylAMac in healthy volunteers, including a single ascending dose study, a multiple ascending dose study, and a food effect study, were successfully completed by AbbVie’s Clinical Pharmacology Research Unit. These studies showed that TylAMac is safe and well tolerated. Next, DNDi will launch a Phase II proof-of-concept study at two recently upgraded clinical trial sites in the Democratic Republic of Congo.
Get our latest news, personal stories, research articles, and job opportunities.